Related to Enobia Chooses Lonza for Commercial-Scale Manufacture of Its Enzyme-Replacement Therapy

• G-Con and GE Healthcare Team Up for Modular Biotherapeutic Manufacturing Solution
  
• Takeda Snags Exclusive License to Baxter’s Vero Cell Culture Tech for Flu Vaccine
  
• Novartis to Build Manufacturing Plant in St. Petersburg as Part of $500M Russian Commitment
  
• Lonza to Leverage IDBS' Data Management and Execution Solution
  
• AMT Secures Option to License Sanfilippo B Gene Therapy from Institut Pasteur-Led Consortium
  
• Boehringer Ingelheim to Purchase Amgen’s Fremont Manufacturing Site
  
• Genzyme to Build €250M Myozyme/Lumizyme Production Plant in Belgium
  
• EMA Road Map Aims to Stimulate Drug Development for Unmet Medical Needs and Rare and Neglected Diseases
  
• Soligenix Nabs Exclusive License to Vaccine Thermostabilization Technology
  
• Oxford BioMedica Buys Manufacturing Facility from RecipharmCobra for £1.9M
  
• Nuron Chooses the Merck BioManufacturing Network for Phase III MS Candidate
  
• Native Antigen Established to Provide Purification Services for IVD Industry
  
• Sanofi-Aventis and Genzyme Finally Agree to $20.1B plus CVR Acquisition Deal
  
• LGLS Licenses Novavax’ VLP Technology to Develop Flu Vaccines for South Korea and Other Emerging Markets
  
• Medicago Achieves $3.8M Milestone under DARPA Contract to Build Vaccine Plant
  
• Biovest and Ordway Research Institute to Evaluate Firm's Technology for Producing Virus-Fighting Products
  
• Pfizer to Attack Lysosomal Storage Diseases with Zacharon’s Small Molecule Approach
  
• CellMed to Leverage Scarab Genomics’ Clean Genome E. coli Technology
  
• Pfizer’s TTR-FAP Candidate Slows Disease Progression in Pivotal Trial Extension
  
• OncoMed and Bayer HealthCare Sign Manufacturing Deal for Partnered Wnt Inhibitor